Buy & Sell Global Payments Inc (GPN) – Global Payments Inc Price Today
Aura AI Summary
Key Stats
- $18.14BMarket Cap
- IndustrialsSector
- -16.18%3M Drawdown
- $35.86BEnterprise Value
- 1.51%Dividend Yield
- 46 daysTypical Hold Time
Global Payments Inc (GPN) is currently valued at a market capitalization of $18.14B, with an enterprise value of $35.86B. Over the past 52 weeks, Global Payments Inc has traded between a low of $62.7 and a high of $90.01, highlighting its annual price range. Over the past three months, Global Payments Inc has recorded a drawdown of -16.18%, reflecting recent price volatility. Global Payments Inc offers a dividend yield of 1.51%, with the most recent dividend of $0.25 paid on 09 Mar 26. On average, investors hold Global Payments Inc for approximately 46 days, indicating typical investor behavior on the platform.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Most Recent News
Tesla's robotaxi fleet shrinks amid safety concerns; SpaceX IPO filing hints at major equity moves.
Tesla has reduced its robotaxi fleet to about 20 vehicles despite expanding the Austin service area, raising safety concerns from former engineers. Meanwhile, SpaceX updated its IPO filing, indicating a lock-in period for Musk's shares and potential ...

AI boom drives strong earnings beats, policy debates, and major tech moves worldwide
Recent financial reports show strong earnings beats driven by surging demand for artificial intelligence (AI) technologies, with companies like ServiceTitan, Palo Alto Networks, and CrowdStrike exceeding revenue and earnings estimates. Policymakers i...

Foundayo leads to significant weight loss in menopausal women, including those with type 2 diabetes, in clinical trials.
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
